Urinary α1 microglobulin level is useful for selecting sodium-glucose transporter 2 inhibitor or metformin for visceral fat reduction in patients with type 2 diabetes

Masaya Koshizaka; Ryoichi Ishibashi; Ko Ishikawa; Mayumi Shoji; Kana Ide; Shintaro Ide; Hisaya Kato; Naoya Teramoto; Ryo Terayama; Yoshiro Maezawa; Koutaro Yokote; PRIME-V Study Group

doi:10.1111/dom.15188

Urinary α1 microglobulin level is useful for selecting sodium-glucose transporter 2 inhibitor or metformin for visceral fat reduction in patients with type 2 diabetes

Diabetes Obes Metab. 2023 Oct;25(10):3071-3075. doi: 10.1111/dom.15188. Epub 2023 Jun 29.

Authors

Masaya Koshizaka^{1

2

3}, Ryoichi Ishibashi^{2

4}, Ko Ishikawa^{1

2}, Mayumi Shoji^{1

2}, Kana Ide^{1

2}, Shintaro Ide^{1

2}, Hisaya Kato^{1

2}, Naoya Teramoto^{1

2}, Ryo Terayama^{1

2}, Yoshiro Maezawa^{1

2}, Koutaro Yokote^{1

2}; PRIME-V Study Group

Affiliations

¹ Department of Medicine, Division of Diabetes, Metabolism and Endocrinology, Chiba University Hospital, Chiba, Japan.
² Department of Endocrinology, Hematology and Gerontology, Chiba University Graduate School of Medicine, Chiba, Japan.
³ Center for Preventive Medical Sciences, Chiba University, Chiba, Japan.
⁴ Department of Medicine, Division of Diabetes, Endocrinology and Metabolism, Kimitsu Chuo Hospital, Chiba, Japan.

PMID: 37385959
DOI: 10.1111/dom.15188

No abstract available

Keywords: SGLT2 inhibitor; body composition; clinical trial; metformin; obesity therapy; type 2 diabetes.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Diabetes Mellitus, Type 2* / drug therapy
Humans
Hypoglycemic Agents / pharmacology
Hypoglycemic Agents / therapeutic use
Intra-Abdominal Fat
Metformin* / therapeutic use
Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use

Substances

Metformin
Sodium-Glucose Transporter 2 Inhibitors
Hypoglycemic Agents